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Abstract
Background/Aims: Sound and rigorous well-established, and newly extended, methods for genetic
epidemiological analysis were used to analyze population evidence for genetic contributions to risk for numerous
common cancer sites in Utah. The Utah Population Database (UPDB) has provided important illumination of the
familial contribution to cancer risk by cancer site.
Methods: With over 15 years of new cancer data since the previous comprehensive familial cancer analysis, we
tested for excess familial clustering using an expanded Genealogical Index of Familiality (dGIF) methodology that
provides for a more informative, but conservative test for the existence of a genetic contribution to familial
relatedness in cancer.
Results: Some new cancer sites have been analyzed for the first time, having achieved sufficiently large sample
size with additions to the UPDB. This new analysis has identified 6 cancer sites with significant evidence for a
heritable contribution to risk, including lip, chronic lymphocytic leukemia, thyroid, lung, prostate, and melanoma.
Conclusions: Both environmentally and genetically-based familial clustering have clinical significance, and these
results support increased surveillance for cancer of the same sites among close relatives of affected individuals for
many more cancers than are typically considered.
Background
The data for this study comes from a well known and
scientifically recognized computerized resource in Utah,
the Utah Population Database (UPDB) [1]. The UPDB
was derived from the computerization of genealogical
data for the Utah pioneers and their descendants. Ori-
ginally it was used as a data resource to study the herit-
ability of cancer risk [2-6]. Over the decades of its
existence the UPDB has evolved to include general
population data, as well as more recent genealogy cre-
ated from Utah State Vital Records (such as mother,
father, child triplets from birth certificates). The UPDB
has been record linked to state death certificates as well
as to diagnosis data from the largest Utah Hospitals and
clinics.
The Utah Cancer Registry (UCR) was established in
1973 and is one of the earliest member state registries
for the Surveillance, Epidemiology, and End Results
(SEER) Program of the National Cancer Institute (NCI)
[7-9]. The individual data in the UPDB continues to be
linked annually to the statewide cancer diagnosis data of
the UCR [10]. The UCR has recorded cancers in the
state since 1966. The combination of genealogy data in
the UPDB with individual cancer data in the UCR allows
genetic epidemiological analysis of familial clustering of
cancer by site.
The most recent published report on familial cluster-
ing of cancer by site in Utah was in 1994 [3]. This cur-
rent study gives an update of evidence for familial
clustering of cancer in Utah, and includes an enhanced
analysis of familiality methodology that allows a more
detailed examination of the heritable contribution to
observed familial clustering. This current analysis of the
latest UPDB linked data has provided larger sample
sizes for all sites previously reported, and includes some
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any medium, provided the original work is properly cited.new sites which have gained sufficient sample sizes since
1994 to be analyzed for the first time.
Methods and data resources
Utah population database
The Utah genealogy data was originally linked to Utah
cancer registry records in the late seventies. The UPDB
has been an important research population database for
the discovery and elucidation of heritable factors for a
wide variety of diseases, including cancer [2-6], influenza
[11], asthma [12], diabetes [13], rotator cuff [14], aneur-
ysm [15], and brain [16], among others. This resource
and the high-risk pedigrees identified within it have
been key for the localization and isolation of multiple
cancer genes, including CDKN2A (melanoma) [17],
BRCA1 [18], BRCA2 [19], and HPC2/ELAC2 (prostate
cancer) [20].
The original Utah genealogy including 1.6 million
Utah individuals has grown to include more than 6.5
million individual records, including 2.3 million indivi-
duals who belong to families of 3 to 15 generations
deep, which connect to the original Utah genealogy. We
have taken advantage of the extended genealogy data to
include more rigorous control of the amount of ances-
tral genealogical data required for an individual to be
included in genetic analyses. To ensure high quality gen-
ealogical records of sufficient depth and breadth for
both cases and for controls, we only consider those indi-
viduals who have ancestral genealogy data for their par-
ents, all four grandparents, and at least 6 of their 8
great grandparents. There were just over 1.2 million
such individuals in the database used for this analysis.
There are 85,550 of these 1.2 million individuals who
also have a cancer record in the UCR between 1966 and
2009. We used ICD-oncology coding as indicated in
Table 1 to assign these 85,550 individuals to 36 different
cancer site groups.
Cancer rates in Utah are recognized to be generally
lower than U.S. rates. Table 2 shows Utah/U.S. inci-
dence rate ratios for cancers as defined and compared
by SEER. Few cancer sites have significantly higher rates
in Utah than the U.S. This is probably due to low rates
of smoking in the Utah population [21].
Genealogical Index of Familiality (GIF) method
The genealogical index of familiality (GIF) is a well-pub-
lished method to test hypotheses of excess relatedness
within sets of individuals selected from the UPDB
[22,23]. The GIF test estimates the average pair-wise
relatedness between all possible pairs within a defined
group of individuals (cases) and compares it to the
expected average relatedness in the UPDB. The average
pairwise relatedness measured by the GIF is based upon
the Malécot coefficient of kinship [24]; the coefficient
gives the probability that randomly selected homologous
genes from 2 individuals are identical by descent from a
common ancestor. For parent-child relationships the
Malécot coefficient is 1/2; for siblings or grandparent
relationships the coefficient is ¼; for avunculars (e.g.,
aunt/niece or aunt/nephew) the coefficient is ⅛; for first
cousins the coefficient is (1/2)
4,o r1/ 16,a n ds of o r t h .
The value of the GIF statistic decreases with increasing
genetic distance between individuals; unrelated indivi-
duals have 0 relatedness. All possible genetic paths
between cases are identified and the average pairwise
relatedness is summed and then averaged for all pairs,
then multiplied by 10
5.
The GIF statistic, or average pair-wise relatedness, for
a set of cases is compared to GIF statistics estimated for
10,000 independent sets of matched controls; controls
are matched by sex, 5 year birth cohorts, and birth state
(Utah or not). The significance of the test of hypothesis
is measured empirically based on the position of the
case GIF in the distribution of 10,000 control GIF statis-
tics. The overall GIF statistic, utilizing all pairwise rela-
tionships between all cases, allows a test of the
alternative hypothesis of no excess clustering over that
expected in the Utah population. A significant result for
the Overall GIF test supports excess relatedness of the
cases; however, it does not distinguish genetic from
familial clustering resulting from shared environment or
risk.
For this reason we have expanded the GIF method to
include a comparison of average relatedness that ignores
close relationships (with a relationship closer than first
cousins). This revised “distant” GIF, or dGIF, statistic
measures relatedness for distant relationships only,
ignoring close relationships where shared environmental
exposures are expected to be highest.
The dGIF statistic is calculated similarly to the origi-
nal GIF, but ignores close relationships among cases,
and among controls. A significant result for the dGIF
test suggests an excess of distant relationships among
case pairs and supports a genetic contribution to the
observed excess relatedness.
F o rt h eG I Ft e s t ,s i n c ew eh a v ep e r f o r m e dm u l t i p l e
tests (on 36 different cancer sites), we have adjusted our
threshold for significance using the Bonferroni correc-
tion (noted to be conservative). We use p < 0.0013
(0.05/36) to identify significant results.
The University of Utah Institutional Review Board,
and the Resource for Genetic Epidemiological Research
approved the research.
Results
The GIF test for excess relatedness was performed for
the 36 different cancer groups shown in Table 1. Even
though we have increased our stringency on the cases to
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Cancer Site Morphology Behavior
Lip 0-9 8000-9589 2-9
Tongue 19-29 8000-9589 2-9
Salivary 79-89 8000-9589 2-9
Pharynx 90-119, 129-39,
140-48
8000-9589 2-9
Esophagus 150-159 8000-9589 2-9
Stomach 160-169 8000-9589 2-9
Small intestine 170-179 8000-9589 2-9
Colon 180, 182-189, 260 8000-8239, 8250-8719 2-9
Rectum 199, 209 8000-8239, 8250-8719 2-9
Anus 210-218 8000-9589 2-9
Liver/hepatic 220, 221 8000-9589 2-9
Gallbladder 239 8000-9589 2-9
Pancreas
a 250-259 8000-1, 8010, 8140-1, 8480-1, 8500 2-9
Larynx 320-329 8000-9589 2-9
Lung/bronchus 340-349 8000-9589 2-9
Bone 400-419 8000-9589 2-9
Melanoma 0-809 8720-8790 2-9
Breast 500-509 8000-9589 2-9
Cervix 530-539 8000-9589 2-9
Endometrial
† 540-549, 559 8010, 8050, 8140, 8210, 8260, 8310, 8323, 8380, 8382, 8441,
8460-1,
8480-81, 8560, 8570
2-9
Ovary 569 8000-9589 2-9
Female Genital (vulva, vagina and other
unspecified)
510-519, 529, 570-
79
8000-9589 2-9
Prostate 619 8000-9589 2-9
Testis 620-629 8000-9589 2-9
Bladder 670-679 8000-9589 2-9
Kidney 649, 659 8000-9589 2-9
Brain 710-719 8000-9529, 9540-9589 2-9
Thyroid 739 8000-9589 2-9
Multiple myeloma 0-809 9732 2-9
Chronic lymphocytic leukemia 0-809 8823 2-9
Acute lymphocytic leukemia 0-809 9821,9828,9831-7 2-9
Chronic myelocytic leukemia 0-809 9863, 9875, 9876 2-9
Acute myelocytic leukemia 0-809 9840,9861,9866-67, 9871-4, 9891, 9895-7, 9920 2-9
Non-Hodgkin’s lymphoma 0-809 9530, 9590-1, 9596, 9598, 9670-1, 9673, 9675, 9678-80, 9684,
9687,
9689-91, 9695, 9698-702, 9705,
9708-9, 9714, 9716-9, 9727-29,
9755, 9764, 9827
2-9
Hodgkin’s lymphoma 0-809 9650-5, 9659, 9661-7, 9945, 9946, 9948 2-9
Oropharynx 19, 24,51-52,
90-91,99,100-104,
108-9
8000-9589 2-9
a Pancreatic adenocarcinoma only
† Excluding endometrial sarcomas
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genealogy data available) sample sizes have still
increased substantially from the 1994 analysis e.g., pros-
tate cancer increased from 8,060 cases in 1994 to 13,933
cases in this study. Nine cancer sites previously not ana-
lyzed due to inadequate sample size in 1994 are pre-
sented here for the first time. These newly analyzed
cancer sites include: larynx (n = 427), female genitals (n
= 365), anus (n = 396), tongue (n = 347), pharynx (n =
315), oropharynx (n = 261), salivary (n = 338), esopha-
gus (n = 520), and bone cancers (n = 294).
Results of the GIF test, shown in Table 3 include the
cancer site, the number of cases, the overall case average
relatedness (case GIF), the average relatedness of con-
trols (mean control GIF), the overall average distant
relatedness (case dGIF), the average distant relatedness
of controls (mean control dGIF), the standard deviation
of the control GIF (SD Control GIF), and the standard
deviation of the control dGIF (SD Control dGIF), the
empirical significance for overall excess of relatedness,
and the empirical significance for the distant relatedness
(dGIF) statistic. The empirical significance for the GIF
test of overall familial clustering (both close and distant)
is the same algorithm used to calculate the GIF in pre-
viously published reports on the familiality of cancer in
Utah [3,4]. The GIF values for both cases and controls
are higher now than in previous publications for two
reasons, we are analyzing more recent birth cohorts and
w ea r eo n l yc o n s i d e r i n gt h o s ei n d i v i d u a l sw i t hs p e c i f i c
ancestral genealogy requirements.
Distant genealogical index of familiality results
We also present, for the first time for cancer, our
e x p a n s i o no ft h eG I Ft e s tt oi n c l u d eat e s tf o re x c e s s
distant relatedness (dGIF). The case, control dGIF statis-
tics, and the empirical significance for the dGIF test are
shown for all cancer sites in Table 3. This analysis iden-
tifies 6 cancer sites for which a significant excess relat-
edness is observed in distant relationships (p < 0.0013,
corrected), strongly supporting a genetic contribution to
cancer predisposition. These 6 cancers include some
with well known genetic effects and already identified
predisposition genes, as well as some for which a genetic
hypothesis has not yet been made. The 6 sites include
chronic lymphocytic leukemia, thyroid, lip, lung, pros-
tate, and melanoma.
We note that some cancers with already identified
predisposition genes (e.g. breast cancer, colon cancer)
did show significant evidence for excess relatedness, but
did not show significant excess familiality under the
dGIF test. Multiple gene identifications of subsets of
breast and colon cancers have provided clear evidence
of a genetic contribution to some portion of these two
cancer sites (considered independently), but it is noted
that the percent of familial cases explained by the
known predisposition genes is low, and that the known
predisposition genes primarily explain dense pedigrees
with close relatives. It therefore may not be a surprise
that the dGIF test shows borderline significance for
colon cancer and is not significant for breast cancer.
We consider the dGIF a conservative test for this rea-
son. Those cancers identified to have a significant dGIF
test represent those cancers with the most significant
evidence for a genetic predisposition, exhibiting excess
risk in distant, as well as in close relatives. However, the
dGIF test is not the only indication for a genetic contri-
bution to predisposition. Typically, when analyzing a
single cancer site, we use both Relative Risk estimates
and GIF tests to more completely test the hypothesis of
a genetic contribution.
Similar to previously published GIF analyses [8,12], we
observed a significant excess of relatedness of cases for
most cancers studied. Before correction for multiple
Table 2 Cancer Incidence Rate Ratio: US/Utah rate ratio
for US without Utah/Utah, by site, for males and females,
1995-2004, for those cancer sites with significantly
higher, or significantly lower rates in Utah than the US
All Cancer Sites Utah Lower Utah Higher
Oral cavity and Pharynx 1.20 (1.19, 1.21)
Esophagus 1.31 (1.24, 1.39)
Stomach 1.66 (1.51, 1.82)
Colon and Rectum 1.51 (1.41, 1.62)
Anus 1.31 (1.27, 1.34)
Liver and intrahepatic bile duct 1.23 (1.06, 1.44)
Pancreas 1.89 (1.72, 2.07)
Larynx 1.32 (1.25, 1.40)
Lung and Bronchus 2.01 (1.80, 2.26)
Melanoma (skin) 0.86 (0.83, 0.89)
Female breast 1.17 (1.14, 1.19)
Cervix uteri 1.24 (1.15, 1.35)
Corpus and uterus, NOS 1.08 (1.03, 1.13)
Ovary 1.07 (1.01, 1.14)
Prostate 0.95 (0.94, 0.97)
Testis 0.86 (0.79, 0.93)
Urinary bladder 1.25 (1.21, 1.30)
Kidney and renal pelvis 1.33 (1.26, 1.40)
Brain and other nervous system 0.94 (0.89, 0.99)
Thyroid 0.82 (0.78, 0.86)
Hodgkin’s lymphoma 1.22 (1.11, 1.35)
Non-Hodgkin’s lymphoma 1.07 (1.03, 1.11)
Myeloma 1.09 (1.02, 1.17)
Leukemia 1.07 (1.03, 1.13)
Rates are per 100,000 and age-adjusted to the 2000 US Standard population
(19 age groups - Census p 25-1130) standard; Confidence intervals are 95%
for rates and ratios [22,23].
Albright et al. BMC Cancer 2012, 12:138
http://www.biomedcentral.com/1471-2407/12/138
Page 4 of 7testing, all but 8 of the cancers considered show signifi-
cant overall excess clustering of cases. The 8 sites not
showing a significant excess even when considered inde-
pendently all have small samples sizes (261 ≤ n ≤ 920)
and many have recognized environmental risk factors (e.
g., esophageal cancer and smoking). Some of the cancers
with a non-significant overall p-value had borderline sig-
nificant excess (e.g. AML and tongue cancer) and some
cancer sites had a much higher case GIF than matched
control GIF (e.g. gallbladder cases = 5.49 and controls =
Table 3 Genealogical Index of Familiality for cancers with at least 200 cases with genealogy data, ranked by empirical
significance for overall excess relatedness (and ranked by case GIF where the overall empirical significance values are
equivalent)
Cancer N Case
GIF
Mean Control
GIF
Case
dGIF
Mean Control
dGIF
SD Control
GIF
SD Control
dGIF
Empirical p
GIF
Empirical p
dGIF
Chronic Lymphocytic
Leukemia
978 7.90 4.76 5.10 4.14 0.26 0.20 < 0.0001 < 0.0001
Small Intestine 387 7.49 4.67 4.56 4.12 0.53 0.38 < 0.0001 0.137
Lip 1077 7.26 4.83 4.89 4.14 0.25 0.20 < 0.0001 0.0001
Thyroid 1865 6.38 4.49 4.48 4.07 0.13 0.11 < 0.0001 0.0006
Testis 691 5.97 4.37 4.18 4.01 0.26 0.20 < 0.0001 0.1943
Multiple Myeloma 1268 5.90 4.76 4.59 4.14 0.21 0.17 < 0.0001 0.0067
Prostate 18069 5.57 4.76 4.44 4.15 0.03 0.03 < 0.0001 < 0.0001
Melanoma 4463 5.56 4.57 4.53 4.11 0.08 0.07 < 0.0001 < 0.0001
Colon 6285 5.49 4.78 4.26 4.13 0.07 0.06 < 0.0001 0.0233
Lung/Bronchus 5063 5.42 4.75 4.27 4.14 0.08 0.07 < 0.0001 0.046
Rectum 2472 5.38 4.73 4.34 4.13 0.13 0.11 < 0.0001 0.032
Kidney 1791 5.35 4.65 4.36 4.12 0.15 0.13 < 0.0001 0.035
Ovary 1941 5.32 4.68 4.27 4.11 0.14 0.12 < 0.0001 0.1042
Non Hodgkin Lymphoma 3267 5.26 4.65 4.44 4.12 0.10 0.08 < 0.0001 0.0002
Breast 12523 5.10 4.70 4.16 4.12 0.04 0.04 < 0.0001 0.2009
Stomach 1490 5.66 4.86 4.32 4.16 0.19 0.16 0.0001 0.1553
Pancreas 1893 5.45 4.77 4.32 4.13 0.16 0.13 0.0001 0.0757
Bladder 2455 5.29 4.84 4.15 4.14 0.13 0.11 0.0008 0.4479
Hodgkin Lymphoma 752 5.25 4.44 3.88 4.03 0.26 0.20 0.0018 0.7628
Endometrial 3155 5.04 4.72 4.03 4.12 0.11 0.09 0.002 0.8261
Cervix 922 5.35 4.68 4.20 4.12 0.26 0.20 0.007 0.3315
Larynx 427 6.06 4.76 4.41 4.14 0.52 0.38 0.0121 0.2366
Brain 1488 4.83 4.45 4.03 4.03 0.16 0.13 0.0124 0.5067
Anus 396 6.33 4.98 4.81 4.17 0.62 0.43 0.0226 0.079
Genital Female 365 6.01 4.75 4.32 4.12 0.60 0.43 0.0266 0.3117
Salivary 338 5.95 4.68 4.52 4.13 0.61 0.44 0.0286 0.1808
Liver/Hepatic 449 5.50 4.63 4.32 4.10 0.47 0.34 0.0418 0.253
Pharynx 315 5.82 4.64 3.30 4.10 0.65 0.46 0.0447 0.9682
Acute Myelogenous
Leukemia
920 5.01 4.62 3.84 4.09 0.25 0.19 0.0651 0.8933
Tongue 347 5.57 4.65 3.49 4.13 0.58 0.42 0.0686 0.9418
Acute Lymphocytic
Leukemia
409 4.58 4.14 3.98 3.83 0.38 0.27 0.1284 0.2822
Gallbladder 306 5.49 4.90 4.15 4.15 0.77 0.53 0.2106 0.4799
Esophagus 520 4.83 4.71 3.90 4.15 0.42 0.31 0.3814 0.7854
Chronic Myelogenous
Leukemia
343 4.59 4.69 4.16 4.10 0.61 0.44 0.5345 0.4319
Oropharynx 261 4.48 4.68 3.37 4.13 0.77 0.54 0.5686 0.9274
Bone 294 3.66 4.34 3.66 3.97 0.56 0.40 0.9014 0.7829
Albright et al. BMC Cancer 2012, 12:138
http://www.biomedcentral.com/1471-2407/12/138
Page 5 of 74.90). Larger sample sizes in future years may clarify
these results.
The GIF statistic values for cancer cases range from
3.66 for bone cancer to 7.90 for chronic lymphocytic
leukemia (this subgroup of leukemia cases was also one
of the highest GIF measures observed in the 1994 analy-
sis). Mean GIF statistics for the 10,000 sets of matched
controls for each site had a smaller range (4.14 - 4.98);
this is as expected in light of the overall similarity we
expect for the estimated pairwise relatedness of ran-
domly selected UPDB controls matched to cancer cases
for 5-year birth cohort and sex. The control GIF mea-
sure represents the average expected relatedness in the
Utah population for older individuals (those represent-
ing the at-risk cancer population). There is also some
expected variability of the control GIF values based on
the birth year distributions for different cancer sites.
Individuals in the UPDB with earlier birth years have
lower relatedness than those born more recently. The
lowest control GIF average (4.14) was for acute lympho-
cytic leukemia; only 20 of 409 ALL cases were born
before 1900; the highest control GIF statistic (4.98) was
for cancer of the anus, 117 of the 396 anus cancer
patients were born before 1900.
Discussion
This analysis of cancer familial clustering provides a
comprehensive review of evidence for familial clustering
of cancer by site using a population-based genealogical
resource linked to statewide cancer data. This analysis
serves to confirm previously reported conclusions sug-
gesting that the majority of cancer sites show some evi-
dence of familial clustering in excess of expected. The
only cancer sites not showing overall significant excess
familial clustering are those with the smaller sample
sizes, suggesting that it may be prudent to await more
data analysis before a conclusion is reached for these
rarer cancers. Using a more stringent, conservative test
for a genetic contribution to cancer predisposition (the
dGIF), this analysis has identified some cancer sites with
significant evidence for a genetic contribution to predis-
position, including very strong evidence for chronic lym-
phocytic leukemia, thyroid cancer, lip cancer, lung
cancer, prostate cancer, and melanoma.
In addition to adding multiple new cancer sites to this
analysis, and multiple new subgroups of cancers, we
additionally used a more stringent selection criteria for
cases and controls, based on amount and quality of gen-
ealogical data available. We propose that this increases
the fidelity of the results and serves to eliminate the
noise in the genealogical resource that comes from ana-
lysis of a greater number of families with incomplete
genealogy compared to analysis of individuals known to
have multiple relatives whose cancer can be observed in
our window of view from 1966. In addition, this filtering
based on quantity of ancestral genealogy has resulted in
slightly higher case GIF statistics than were observed in,
for example, the 1994 analysis.
The results for the overall GIF test show that for most
of the cancer sites examined (28 of 36) there is a signifi-
cant excess overall relatedness observed (without correc-
tion). This is similar to the results shown in Cannon-
Albright et al., 1994, the most recent published Utah
GIF analysis. In that previous analysis, all cancer sites
except small intestine, gallbladder, kidney, liver, pan-
creas, and uterus (termed endometrial in this analysis)
showed significant overall excess relatedness (at p <
0.05). With larger sample sizes, we now see significant
excess cancer clustering of the small intestine, kidney,
liver, pancreas, and uterus (endometrial). Of the new
sites we have added to this analysis, larynx, anus, sali-
vary, pharynx and female genitals show significant over-
all excess familial clustering. The list of cancers that
failed to show excess overall familial clustering primarily
includes those with the smallest sample sizes. Separate
analyses of cancers have identified subgroups with evi-
dence for a genetic contribution [16,25-27].
The familiality analyses reported here has been limited
in terms of the availability of data. Cancers diagnosed
before 1966 or outside of Utah are censored; similarly
individuals whose genealogy data was not included in
the UPDB, or whose data did not appropriately link to
their cancer data are also censored. We assume such
censoring to be unbiased in nature. Because the GIF
analysis considers relationships that are observed, it is
robust to such censoring, but may be conservative in its
identification of strong evidence for a heritable predis-
position to disease.
Increases in computing power have allowed us to
increase the number of matched controls groups ana-
lyzed from n = 6 in 1982, to 100 in 1994, to 10,000 in
this analysis. It has similarly allowed us to consider both
overall excess relatedness, as well as excess relatedness
due only to distant relationships, the key to being able
to separate what could be clustering due to shared
environment from clustering that appears much more
likely to be due to shared genetic factors.
Conclusions
Although we report several cancer sites with strong evi-
dence for a genetic contribution, the implications of the
results reported here go beyond genetic predisposition
to disease. For almost all cancer sites analyzed, we
observed an excess of familial clustering; most of this
evidence is based on an excess of close relationships
among cases. Whether based on the existence of shared
environment or of shared genetics or a combination, the
clinical implications are the same: close relatives of
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Page 6 of 7individuals with cancer are at increased risk for cancer
of that same site. This is true for cancers of many differ-
ent sites, and this should be considered when making
decisions on cancer screening or recommendations for
lifestyle changes.
The implications for those cancers with evidence for
both close and distant excess relatedness are also clear.
There must exist genes or gene variants that are respon-
sible for the clustering observed in the Utah population.
Multiple cancer predisposition genes have already been
identified in high-risk Utah pedigrees identified in the
UPDB, including BRCA1, BRCA2,a n dp16/CDKN2A
[17-19]. The newly reported cancers of most interest for
a genetic contribution to predisposition (lip cancer,
non-Hodgkin lymphoma and multiple myeloma) should
be the focus of high-risk pedigree studies to identify the
hypothesized predisposition genes for which we present
evidence. Such studies have begun in Utah, and our
findings may have implications for cancer screening and
risk assessment.
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